

Veli-Matti Kähäri, MD, PhD

LIST OF PUBLICATIONS 20.11.2018

150 Original publications, 51 reviews or book chapters

Total citations 14037 (Thomson Reuters Web of Science November 20, 2018)

H-Index 63 (Thomson Reuters Web of Science November 20, 2018)

A. Peer-reviewed scientific articles

a. Original articles

1. Kähäri VM, Vuorio T, Nantö-Salonen K, Vuorio E (1984) Increased type I collagen mRNA levels in cultured scleroderma fibroblasts. *Biochim Biophys Acta* 781:183-186.
2. Vuorio TK, Kähäri VM, Lehtonen A, Vuorio EI (1984) Fibroblast activation in scleroderma. *Scand J Rheumatol* 13:229-237.
3. Vuorio T, Mäkelä JK, Kähäri VM, Vuorio E (1987) Coordinated regulation of type I and type III collagen production and mRNA levels of pro α 1(I) and pro α 2(I) collagen in cultured morphea fibroblasts. *Arch Dermatol Res* 279:154-160.
4. Mäkinen J, Kähäri VM, Söderström K-O, Vuorio E, Hirvonen T (1987) Collagen synthesis in the vaginal connective tissue of patients with and without uterine prolapse. *Eur J Obstet Gyn Reprod Biol* 24:319-325.
5. Kähäri VM, Multimäki P, Vuorio E (1987) Elevated pro α 2(I) collagen mRNA levels in cultured scleroderma fibroblasts result from an increased transcription rate of the corresponding gene. *FEBS Lett* 215:331-334.
6. Kähäri VM, Vuorio E (1987) Increased half-lives of procollagen mRNAs may contribute to the elevated procollagen mRNA levels in cultured scleroderma fibroblasts. *Med Sci Res* 15:417-418.
7. Kähäri VM, Heino J, Larjava H, Vuorio E (1987) Alterations in scleroderma fibroblast surface glycoproteins associated with increased collagen synthesis. *Acta Dermato Venereol (Stockh)* 67:199-205.
8. Kähäri VM, Heino J, Vuorio E (1987) Interleukin-1 increases collagen production and mRNA levels in cultured skin fibroblasts. *Biochim Biophys Acta* 929:142-147.
9. Laato M, Kähäri VM, Niinikoski J, Vuorio E (1987) Epidermal growth factor increases collagen production in granulation tissue by stimulation of fibroblast proliferation and not by activation of procollagen genes. *Biochem J* 247:385-388.
10. Kähäri VM (1987) Regulation of procollagen gene expression in localized scleroderma. Studies on an activated fibroblast phenotype. Doctoral Thesis. University of Turku, 1-60. ISBN 951-99870-0-2.
11. Kähäri VM, Heino J, Vuorio T, Vuorio E (1988) Interferon- α and interferon- γ reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in

- culture. *Biochim Biophys Acta* 968:45-50.
12. Mauviel A, Kähäri VM, Heino J, Daireaux M, Hartmann DJ, Loyau G, Pujol J-P (1988) Gene expression of fibroblast matrix proteins is altered by indomethacin. *FEBS Lett* 231:125-129.
 13. Heino J, Kähäri VM, Mauviel A, Krusius T (1988) Human recombinant interleukin-1 regulates cellular mRNA levels of dermatan sulphate proteoglycan core protein. *Biochem J* 252:309-312.
 14. Kähäri VM, Sandberg M, Kalimo H, Vuorio T, Vuorio E (1988) Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. *J Invest Dermatol* 90:664-670.
 15. Kähäri VM, Eerola E, Vuorio E (1988) Flow cytometry of fibroblasts cultured from skin of patients with localized scleroderma. *Dermatology* 177:348-353.
 16. Heino J, Kähäri VM, Jaakkola S, Peltonen J (1989) Collagen in the extracellular matrix of cultured scleroderma skin fibroblasts: Changes related to ascorbic acid-treatment. *Matrix Biol* 9: 34-39.
 17. Larjava H, Heino J, Kähäri VM, Krusius T, Vuorio E (1989) Characterization of one phenotype of human periodontal granulation tissue fibroblasts. *J Dent Res* 68:20-25.
 18. Laato M, Heino J, Kähäri VM, Niinikoski J, Gerdin B (1989) Epidermal growth factor (EGF) prevents methylprednisolone-induced inhibition of wound healing. *J Surg Res* 47:354-359.
 19. Fazio MJ, Kähäri VM, Bashir MM, Saitta B, Rosenbloom J, Uitto J (1990) Regulation of elastin gene expression: Evidence for functional promoter activity in the 5'-flanking region of the human gene. *J Invest Dermatol* 94:191-196.
 20. Peltonen J, Kähäri L, Jaakkola S, Kähäri VM, Varga J, Uitto J, Jimenez SA (1990) Evaluation of transforming growth factor- β and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization. *J Invest Dermatol* 94:365-371.
 21. Kähäri VM, Heino J, Niskanen L, Fräki J, Uitto J (1990) Eosinophilic fasciitis. Increased collagen production and type I procollagen messenger RNA levels in fibroblasts cultured from involved skin. *Arch Dermatol* 126:613-617.
 22. Kähäri VM, Fazio MJ, Chen YQ, Bashir MM, Rosenbloom J, Uitto J (1990) Deletion analyses of 5'-flanking region of the human elastin gene: Delineation of functional promoter and regulatory *cis*-elements. *J Biol Chem* 265:9485-9490.
 23. Kähäri VM, Chen YQ, Su MW, Ramirez F, Uitto J (1990) Tumor necrosis factor- α and interferon- γ suppress the activation of human type I collagen gene expression by transforming growth factor- β 1: Evidence for two distinct mechanisms of inhibition at transcriptional and post-transcriptional level. *J Clin Invest* 86:1489-1495.
 24. Mauviel A, Heino J, Kähäri VM, Hartmann DJ, Loyau G, Pujol J-P, Vuorio E (1991) Comparative effects of interleukin-1 and tumor necrosis factor- α on collagen production and corresponding procollagen mRNA levels in human dermal fibroblasts. *J Invest*

Dermatol 96:243-249.

25. Vuorio T, Kähäri VM, Black C, Vuorio E (1991) Expression of osteonectin, decorin and transforming growth factor- β 1 genes in fibroblasts cultured from patients with systemic sclerosis and morphea. *J Rheumatol* 18:247-251.
26. Kähäri VM, Larjava H, Uitto J (1991) Differential regulation of extracellular matrix proteoglycan (PG) gene expression: Transforming growth factor- β 1 upregulates biglycan (PG I), and versican (large fibroblast PG) but down-regulates decorin (PG II) mRNA levels in human fibroblasts in culture. *J Biol Chem* 266:10608-10615.
27. Kähäri VM, Peltonen J, Chen YQ, Uitto J (1991) Differential modulation of basement membrane gene expression in human fibrosarcoma HT-1080 cells by transforming growth factor- β 1. Enhanced type IV collagen and fibronectin gene expression correlates with altered culture phenotype of the cells. *Lab Invest* 64:807-818.
28. Fazio MJ, O'Leary J, Kähäri VM, Chen YQ, Saitta B, Uitto J (1991) Human nidogen gene: Structural and functional characterization of the 5'-flanking region. *J Invest Dermatol* 97:281-285.
29. Mauviel A, Kähäri VM, Evans C, Uitto J (1992) Transcriptional activation of fibroblast collagenase gene expression by a novel lymphokine, leukoregulin. *J Biol Chem* 267:5644-5648.
30. Kähäri VM, Olsen DR, Rhudy RW, Carrillo P, Chen YQ, Uitto J (1992) Transforming growth factor- β up-regulates elastin gene expression in human skin fibroblasts. Evidence for post-transcriptional modulation. *Lab Invest* 66:580-588.
31. Mauviel A, Kähäri VM, Kurkinen M, Evans CH, Uitto J (1992) Leukoregulin, a T-cell derived cytokine, upregulates stromelysin-1 gene expression in human dermal fibroblasts: Evidence for the role of AP-1 in transcriptional activation. *J Cell Biochem* 50:53-61.
32. Kähäri VM, Chen YQ, Bashir MM, Rosenbloom J, Uitto J (1992) Tumor necrosis factor- α down-regulates human elastin gene expression. Evidence for the role of AP-1 in the suppression of promoter activity. *J Biol Chem* 267:26134-26141.
33. Mauviel A, Chen YQ, Kähäri VM, Ledo I, Wu M, Rudnicka L, Uitto J (1993) Human recombinant interleukin-1 β up-regulates elastin gene expression in dermal fibroblasts. Evidence for transcriptional regulation *in vitro* and *in vivo*. *J Biol Chem* 268:6520-6524.
34. Lohi J, Kähäri VM, Keski-Oja J (1994) Cyclosporin-A enhances cytokine and phorbol ester induced fibroblast collagenase expression. *J Invest Dermatol* 102:938- 944.
35. Kähäri VM (1994) Dexamethasone suppresses elastin gene expression in human skin fibroblasts in culture. *Biochem Biophys Res Commun* 201:1189-1196.
36. Westermarck J, Lohi J, Keski-Oja J, Kähäri VM (1994) Okadaic acid-elicited transcriptional activation of collagenase gene expression in HT-1080 fibrosarcoma cells is mediated by JunB. *Cell Growth Differ* 5:1205-1213.

37. Kähäri VM, Häkkinen L, Westermarck J, Larjava H (1995) Differential regulation of decorin and biglycan gene expression by dexamethasone and retinoic acid in cultured human skin fibroblasts. *J Invest Dermatol* 104: 503-508.
38. Westermarck J, Ilvonen E, Uitto J, Kähäri VM (1995) Suppression of elastin gene expression in dermal fibroblasts by protein phosphatase inhibitor okadaic acid. *Biochem Biophys Res Commun* 209:175-181.
39. Westermarck J, Ilvonen E, Kähäri VM (1995) The protein phosphatase inhibitor okadaic acid suppresses type I collagen gene expression in cultured fibroblasts at the transcriptional level. *Biochem J* 308:995-999.
40. Riikonen T, Westermarck J, Koivisto L, Broberg A, Kähäri VM, Heino J (1995) Integrin $\alpha 2\beta 1$ is a positive regulator of collagenase (MMP-1) and collagen $\alpha 1(I)$ gene expression. *J Biol Chem* 270:13548-13552.
41. Westermarck J, Häkkinen L, Fiers W, Kähäri VM (1995) TNF-R55-specific form of human tumor necrosis factor- α induces collagenase gene expression by human skin fibroblasts. *J Invest Dermatol* 105:197-202.
42. Lohi J, Lehti K, Westermarck J, Kähäri VM, Keski-Oja J (1996) Regulation of membrane type metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. *Eur J Biochem* 239:239-247.
43. Häkkinen L, Westermarck J, Kähäri VM, Larjava H (1996) Human granulation-tissue fibroblasts show enhanced proteoglycan gene expression and an altered response to TGF- $\beta 1$. *J Dent Res* 75:1767-1778.
44. Johansson N, Westermarck J, Leppä S, Häkkinen L, Koivisto L, López-Otín C, Peltonen J, Heino J, Kähäri VM (1997) Collagenase-3 (matrix metalloproteinase-13) gene expression by HaCaT keratinocytes is enhanced by tumor necrosis factor- α and transforming growth factor- β . *Cell Growth Differ* 8:243-250.
45. Johansson N, Saarialho-Kere U, Airola K, Herva R, Nissinen L, Westermarck J, Vuorio E, Heino J, Kähäri VM (1997) Collagenase-3 (MMP-13) is expressed by hypertrophic chondrocytes, periosteal cells, and osteoblasts during human fetal bone development. *Dev Dyn* 208:387-397.
46. Westermarck J, Seth A, Kähäri VM. (1997) Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. *Oncogene* 14:2651-2660.
47. Vaalamo M, Mattila L, Johansson N, Kariniemi A-L, Karjalainen-Lindsberg M-L, Kähäri VM, Saarialho-Kere U (1997) Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. *J Invest Dermatol* 109:96-101.
48. Johansson N, Airola K, Grénman R, Kariniemi A-L, Saarialho-Kere U, Kähäri VM. (1997) Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. *Am J Pathol* 151:499-508.

49. Airola K, Johansson N, Kariniemi A-L, Kähäri VM, Saarialho-Kere UK. (1997) Human collagenase-3 is expressed in malignant squamous epithelium of the skin. *J Invest Dermatol* 109:225-231.
50. Häkkinen L, Westermarck J, Johansson N, Aho H, Peltonen J, Heino J, Kähäri VM. (1998) Suprabasal expression of epidermal $\alpha 2\beta 1$ and $\alpha 3\beta 1$ integrins in skin treated with topical retinoic acid. *Brit J Dermatol* 138: 29-36.
51. Reunanen N, Westermarck J, Häkkinen L, Holmström TH, Elo I, Eriksson JE, Kähäri VM. (1998) Enhancement of fibroblast collagenase-1 (Matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. *J Biol Chem* 273:5137-5145.
52. Isoherranen K, Westermarck J, Kähäri VM, Jansén C, Punnonen K. (1998) Differential regulation of the AP-1 family members by UV irradiation *in vitro* and *in vivo*. *Cell Signal* 10:191-195.
53. Mattila L, Airola K, Ahonen M, Hietarinta M, Black C, Saarialho-Kere U, Kähäri VM (1998) Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. *J Invest Dermatol* 110: 416-421.
54. Airola K, Ahonen M, Johansson N, Heikkilä P, Kere J, Kähäri VM, Saarialho-Kere UK. (1998) Human TIMP-3 is expressed during fetal development, hair growth cycle, and cancer progression. *J Histochem Cytochem* 46: 437-448.
55. Uitto V-J, Airola K, Vaalamo M, Johansson N, Putnins EE, Firth JD, Salonen J, López-Otín C, Saarialho-Kere U, Kähäri VM. (1998) Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation. *Am J Pathol* 152: 1489-1499.
56. Ahonen M, Baker AH, Kähäri VM. (1998) Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. *Cancer Res* 58:2310-2315.
57. Nissinen L, Westermarck J, Koivisto L, Kähäri VM, Heino J. (1998) Transcription of $\alpha 2$ integrin gene in osteosarcoma cells is enhanced by tumor promoters. *Exp Cell Res* 243:1-10.
58. Nelimarkka L, Nikkari S, Ravanti LS, Kähäri VM, Järveläinen H. (1998) Collagenase-1, stromelysin-1 and 92 kDa gelatinase are associated with tumor necrosis factor- α induced morphological change of human endothelial cells *in vitro*. *Matrix Biol* 17:293-304.
59. Westermarck J, Holmström TH, Ahonen M, Eriksson JE, Kähäri VM. (1998) Enhancement of fibroblast collagenase-1 (MMP-1) gene expression by tumor promoter okadaic acid is mediated by stress-activated protein kinases Jun N-terminal kinase and p38. *Matrix Biol* 17:547-557.

60. Ravanti L, Heino J, López-Otín C, Kähäri VM. (1999) Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase. *J Biol Chem* 74:2446-2455.
61. Johansson N, Vaalamo M, Grénman S, Hietanen S, Klemi P, Saarialho-Kere U, Kähäri VM. (1999) Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. *Am J Pathol* 154:469-478.
62. Ivaska J, Reunanen H, Westermarck J, Koivisto L, Kähäri VM, Heino J. (1999) Integrin $\alpha 2\beta 1$ mediates isoform-specific activation of p38 and upregulation of collagen gene transcription by a mechanism involving the $\alpha 2$ cytoplasmic tail. *J Cell Biol* 147: 401-415.
63. Ravanti L, Häkkinen L, Larjava H, Saarialho-Kere U, Foschi M, Han J, Kähäri VM (1999) Transforming growth factor- β induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase. *J Biol Chem* 274:37292-37300.
64. Johansson N, Ala-aho R, Uitto V-J, Grénman R, Fusenig NE, López-Otín C, Kähäri VM. (2000) Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. *J Cell Sci* 113:227-235.
65. Ala-aho R, Johansson N, Grénman R, Fusenig NE, López-Otín C, Kähäri VM. (2000) Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon- γ is associated with activation of extracellular signal-regulated kinase1,2 and STAT1. *Oncogene* 19:248-257.
66. Inkinen K, Turakainen H, Wolff H, Ravanti L, Kähäri VM, Ahonen J. (2000) Expression and activity of matrix metalloproteinase-2 and -9 in experimental granulation tissue. *APMIS* 108:318-328.
67. Kerkelä E, Ala-aho R, Jeskanen L, Rechart O, Grénman R, Shapiro SD, Kähäri VM, Saarialho-Kere U. (2000) Expression of human macrophage metalloelastase (MMP-12) by tumor cells in skin cancer. *J Invest Dermatol* 114:1113-1119.
68. Laine P, Reunanen N, Ravanti L, Foschi M, Santra M, Iozzo RV, Kähäri VM. (2000) Activation of extracellular signal-regulated protein kinase1,2 results in down-regulation of decorin expression in fibroblasts. *Biochem J* 349:19-25
69. Jaakkola P, Ahonen M, Kähäri VM, Jalkanen M. (2000) Transcriptional targeting of adenoviral gene delivery into migrating wound keratinocytes using FiRE, a growth factor-inducible regulatory element. *Gene Ther* 7:1640-1647.
70. Ekholm EC, Ravanti L, Kähäri VM, Paavolainen P, Penttinen RPK. (2000) Expression of extracellular matrix genes, transforming growth factor (TGF)- $\beta 1$ and *ras* in tibial fracture healing of lathyritic rats. *Bone* 27:551-557
71. Boström PJ, Ravanti L, Reunanen N, Aaltonen V, Södeström K-O, Kähäri VM, Laato M. (2000) Expression of collagenase-3 (matrix metalloproteinase-13) in transitional cell carcinoma of the urinary bladder. *Int J Cancer* 88: 417-423

72. Reunanen N, Foschi M, Han J, Kähäri VM. (2000) Activation of extracellular signal-regulated kinase-1/2 inhibits type I collagen expression by human skin fibroblasts. *J Biol Chem* 275: 34634-34639
73. Westermarck J, Li S, Jaakkola P, Kallunki T, Grénman R, Kähäri VM. (2000) Activation of fibroblast collagenase-1 expression by tumor cells of squamous cell carcinomas is mediated by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase-2. *Cancer Res* 60:7156-7162
74. Häkkinen L, Strassburger S, Kähäri VM, Scott PG, Eichstetter I, Iozzo RV, Larjava H. (2000) A role for decorin in the structural organization of periodontal ligament. *Lab Invest* 80:1869-1880.
75. Kerkelä E, Ala-aho R, Jeskanen L, Lohi J, Grénman R, Kähäri VM, Saarialho-Kere U. (2001) Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancer. *Br J Cancer* 84:659-669
76. Westermarck J, Li S-P, Kallunki T, Han J, Kähäri VM. (2001) p38 mitogen-activated protein kinase-dependent activation of protein phosphatases 1 and 2A inhibits MEK1 and MEK2 activity and collagenase-1 (MMP-1) gene expression. *Mol Cell Biol* 21:2373-2383
77. Ravanti L, Toriseva M, Penttinen R, Crombleholme T, Foschi M, Han J, Kähäri VM. (2001) Expression of human collagenase-3 (MMP-13) by fetal skin fibroblasts is induced by transforming growth factor β via p38 mitogen-activated protein kinase. *FASEB J* 15:1098-1100.
78. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kähäri VM, Pyrhönen S. (2001) High collagenase-1 expression correlates with a favourable chemoimmunotherapy response in human metastatic melanoma. *Melanoma Res* 11:157-166.
79. Uusitalo H, Hiltunen A, Ahonen M, Kähäri VM, Aro H, Vuorio E. (2001) Induction of periosteal callus formation by bone morphogenetic protein-2 employing adenovirus-mediated gene delivery. *Matrix Biol* 20:123-127.
80. Tran SEF, Holmström TH, Ahonen M, Kähäri VM, Eriksson JE. (2001) MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. *J Biol Chem* 276:16484-16490
81. Uusitalo H, Rantakokko J, Ahonen M, Jämsä T, Tuukkanen J, Kähäri VM, Vuorio E, Aro HT. (2001) A metaphyseal defect model of the femur for studies of murine bone healing. *Bone* 28:423-429.
82. Söderström M, Aro H, Ahonen M, Johansson N, Aho A, Ekfors T, Kähäri VM, Vuorio E. (2001) Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. *APMIS* 109:305-315.
83. Uusitalo H, Hiltunen A, Ahonen M, Gao T-J, Lefebvre V, Harley V, Kähäri VM, Vuorio E. (2001) Accelerated up-regulation of L-Sox5, Sox6, and Sox9 by BMP-2 gene

- transfer during murine fracture healing. *J Bone Miner Res* 16:1837-1845.
84. Ala-aho R, Johansson N, Baker AH, Kähäri VM. (2002) Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells. *Int J Cancer* 97: 283-289
 85. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kähäri VM, Pyrhönen S. (2002) High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. *Int J Cancer* 97: 432-438
 86. Chen Z, Ahonen M, Hämäläinen H, Bergelson JM, Kähäri VM, Lahesmaa R. (2002) High-efficiency gene transfer to primary T lymphocytes by recombinant adenovirus vectors. *J Immunol Methods* 260:79-89
 87. Ivaska J, Nissinen L, Immonen N, Eriksson JE, Kähäri VM, Heino J. (2002) Integrin $\alpha 2\beta 1$ promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3β . *Mol Cell Biol* 22:1352-1359
 88. Ala-aho R, Grénman R, Seth P, Kähäri VM. (2002) Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells. *Oncogene* 21:1187-95
 89. Ahonen M, Ala-aho R, Baker AH, George SJ, Grénman R, Saarialho-Kere U, Kähäri VM. (2002) Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. *Mol Ther* 6: 705-715.
 90. Laato M, Heino J, Gerdin B, Kähäri VM, Niinikoski J. (2002) Interferon- γ -induced inhibition of wound healing in vivo and in vitro. *Ann Chir Gynecol* 90 (suppl 215) 19-23
 91. Reunanen N, Li S-P, Ahonen M, Foschi M, Han J, Kähäri VM. (2002) Activation of p38 α MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. *J Biol Chem* 277: 32360-32368.
 92. Kerkelä E, Ala-aho R, Klemi P, Grénman S, Shapiro S, Kähäri VM, Saarialho-Kere U. (2002) Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. *J Pathol* 198:258-69.
 93. Leivonen S, Chantry A, Häkkinen L, Han J, Kähäri VM. (2002) Smad3 mediates transforming growth factor- β -induced collagenase-3 (matrix metalloproteinase-13) expression in human gingival fibroblasts. Evidence for cross-talk between Smad3 and p38 signaling pathways. *J Biol Chem* 277:46338-46346.
 94. Impola U, Toriseva M, Suomela S, Jeskanen L, Hieta N, Jahkola T, Grénman R, Kähäri VM, Saarialho-Kere U. (2003) Matrix metalloproteinase-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation. *Int J Cancer* 103:709-716.
 95. Ahonen M, Poukkula M, Baker AH, Kashiwagi M, Nagase H, Eriksson JE, Kähäri VM. (2003) Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by

stabilization of death receptors. *Oncogene* 22:2121-2134.

96. Li S-P, Junttila MR, Han J, Kähäri VM, Westermarck J. (2003) p38 mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase1,2. *Cancer Res* 63:3473-3477.
97. Hieta N, Impola U, López-Otín C, Saarialho-Kere U, Kähäri VM. (2003) Matrix metalloproteinase-19 expression in dermal wounds and by fibroblasts in culture. *J Invest Dermatol* 121:997-1004.
98. Joronen K, Ala-aho R, Majuri M-L, Alenius H, Kähäri VM, Vuorio E. (2004) Adenovirus-mediated intra-articular expression of collagenase-3 (MMP-13) induces inflammatory arthritis in mice. *Ann Rheum Dis* 63:656-664.
99. Ala-aho R, Ahonen M, George SJ, Heikkilä J, Grénman R, Kallajoki M, Kähäri VM. (2004). Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth *in vivo*. *Oncogene* 23:5111-5123.
100. Koistinen P, Ahonen M, Kähäri VM, Heino J (2004). α V integrin promotes *in vitro* and *in vivo* survival of cells in metastatic melanoma. *Int J Cancer* 112:61-70.
101. Impola U, Jeskanen L, Ravanti L, Syrjänen S, Baldursson B, Kähäri VM, Saarialho-Kere U. (2005) Expression of matrix metalloproteinase-7 (MMP-7) and -13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds. *Brit J Dermatol* 152:720-726.
102. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kähäri VM, Pyrhönen S. (2005) High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. *Clin Cancer Res* 11:5158-5166
103. Leivonen S-K, Häkkinen L, Liu D, Kähäri VM. (2005) Smad3 and extracellular signal-regulated kinase 1/2 coordinately mediate transforming growth factor- β -induced expression of connective tissue growth factor in human fibroblasts. *J Invest Dermatol* 124:1162-1169
104. Joronen K, Kähäri VM, Vuorio E. (2005) Temporospatial expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in mouse antigen induced arthritis. *Histochem Cell Biol* 124:535-545.
105. Luukkaa M, Vihinen P, Kronqvist P, Vahlberg T, Pyrhönen S, Kähäri VM, Grénman R. (2006) Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. *Head Neck* 28:225-234.
106. Shinozaki K, Suominen E, Carrick F, Sauter B, Kähäri VM, Lieber A, Woo SLC, Savontaus M. (2006) Efficient infection of tumor endothelial cells by a capsid-modified adenovirus. *Gene Ther* 13:52-59.
107. Leivonen S-K, Ala-aho R, Koli K, Grénman R, Peltonen J, Kähäri VM. (2006) Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and

- invasion of head and neck squamous carcinoma cells. *Oncogene* 25:2588-2600.
108. Rönty MJ, Leivonen SK, Hinz B, Rachlin A, Otey CA, Kähäri VM, Carpen OM. (2006) Isoform-specific regulation of the actin-organizing protein palladin during TGF- β 1-induced myofibroblast differentiation. *J Invest Dermatol* 126:2387-2396.
 109. Vähä-Koskela MJ, Kallio JP, Jansson LC, Heikkilä JE, Zakhartchenko VA, Kallajoki MA, Kähäri VM, Hinkkanen AE. (2006) Oncolytic capacity of attenuated replicative Semliki Forest Virus in human melanoma xenografts in severe combined immunodeficient mice *Cancer Res* 66:7185-7194.
 110. Toriseva MJ, Ala-aho R, Karvinen J, Baker AH, Marjomäki VS, Heino J, Kähäri VM. (2007) Collagenase-3 (MMP-13) enhances remodeling of three-dimensional collagen and promotes survival of human skin fibroblasts. *J Invest Dermatol* 127:49-59.
 111. Junttila MR, Ala-aho R, Jokilehto T, Peltonen J, Kallajoki M, Grénman R, Jaakkola P, Westermarck J, Kähäri VM. (2007) p38 α and p38 δ mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. *Oncogene* 26:5267-5279.
 112. Kajanne R, Miettinen P, Mehlem A, Leivonen S-K, Birrer M, Foschi M, Kähäri VM, Leppä S. (2007) EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. *J Cell Physiol* 212:489-97
 113. Vihinen PP, Hilli J, Vuoristo MS, Syrjänen KJ, Kähäri VM, Pyrhönen SO. (2007) Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. *Acta Oncol* 46:678-84.
 114. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu S-L, Lin S, Chan EKL, Wang X-J, Grénman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J (2007) CIP2A inhibits PP2A in human malignancies. *Cell* 130: 51-62.
 115. Kivisaari AK, Kallajoki M, Mirtti T, McGrath JA, Bauer JW, Weber F, Königová R, Sawamura D, Sato-Matsumura KC, Shimizu H, Csikós M, Sinemus K, Beckert W, and Kähäri V.-M. (2008) Transformation specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas. *Brit J Dermatol* 158:778-85.
 116. Sebe A, Leivonen SK, Fintha A, Masszi A, Rosivall L, Kähäri VM, Mucsi I. (2008) Transforming growth factor- β induced α -smooth muscle cell actin expression in renal proximal tubular cells is regulated by p38 β mitogen activated protein kinase, extracellular signal regulated protein kinase1,2 and the Smad signalling during epithelial-myofibroblast transdifferentiation. *Nephrol Dial Transplant* 3:1537-45.
 117. Luukkaa H, Klemi P, Hirsimäki P, Vahlberg T, Kivisaari A, Kähäri VM, Grénman R (2008) Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer. *Acta Otolaryngol* 128:482-90.

118. Kangasniemi L, Koskinen M, Jokinen M, Toriseva M, Ala-aho R, Kähäri VM, Jalonen H, Ylä-Herttua S, Moilanen H, Stenman U-H, Diaconu I, Kanerva A, Pesonen S, Hakkarainen T, Hemminki A. (2009) Extended release of adenovirus from silica implants *in vitro* and *in vivo*. *Gene Ther* 16:103-10.
119. Suomela S, Elomaa O, Skoog T, Ala-aho R, Jeskanen L, Pärssinen J, Latonen L, Grénman R, Kere J, Kähäri VM, Saarialho-Kere U. (2009) CCHCR1 is up-regulated in skin cancer and associated with EGFR expression. *PLoS One* 24;4(6):e6030
120. Luukkaa H, Klemi P, Hirsimäki P, Vahlberg T, Kivisaari A, Kähäri VM, Grénman R (2010) Matrix metalloproteinase (MMP) -7 in salivary gland cancer *Acta Oncol* 49:85-90
121. Heikkinen PT, Nummela M, Leivonen SK, Westermarck J, Hill CS, Kähäri VM, Jaakkola PM. (2010) Hypoxia activated Smad3-specific dephosphorylation by PP2A. *J Biol Chem* 285:3740-9.
122. Luukkaa H, Klemi P, Leivo I, Mäkitie AA, Irish J, Gilbert R, Perez-Ordóñez B, Hirsimäki P, Vahlberg T, Kivisaari A, Kähäri VM, Grénman R. (2010) Expression of matrix metalloproteinase-1, -7, -9 -13, Ki-67 and HER-2 in epithelial-myoepithelial salivary gland cancer. *Head Neck* 32:1019-27
123. Stokes A, Joutsa J, Ala-aho R, Pitchers M, Pennington CJ, Martin C, Premachandra DJ, Okada Y, Peltonen J, Grénman R, James HA, Edwards DR, Kähäri VM (2010) Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. *Clin Cancer Res* 16:2022-35.
124. Heikkinen PT, Nummela M, Jokilehto T, Grénman R, Kähäri VM, Jaakkola PM. (2010) Hypoxic conversion of SMAD7 function from an inhibitor into a promoter of cell invasion. *Cancer Res* 70:5984-93
125. Laihia JK, Kallio JP, Taimen P, Kujari H, Kähäri VM, Leino L. (2010) Protodynamic intracellular acidification by *cis*-urocanic acid promotes apoptosis of melanoma cells *in vitro* and *in vivo*. *J Invest Dermatol* 130:2431-9.
126. Kivisaari AK, Kallajoki M, Ala-aho R, McGrath JA, Bauer JW, Königová R, Medvez M, Beckert W, Grénman R, Kähäri VM. (2010) Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma. *Brit J Dermatol* 163:726-735.
127. Bradshaw AC, Parker AL, Duffy MR, Coughlan L, Van Rooijen N, Kähäri VM, Nicklin SA, Baker AH. (2010) Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. *PLoS Pathog* 6(10): e1001142.
128. Kallio JP, Hopkins-Donaldson S, Baker AH, Kähäri VM. (2011) TIMP-3 promotes apoptosis in non-adherent small cell lung carcinoma cells lacking functional death receptor pathway *Int J Cancer* 128:991-6
129. Endo H, Niioka M, Sugioka Y, Itoh J, Kameyama K, Okazaki I, Ala-Aho R, Kähäri VM, Watanabe T. (2011) Matrix metalloproteinase-13 promotes recovery from

experimental liver cirrhosis in rats. *Pathobiology* 78:239-252

130. Farshchian M, Kivisaari A, Ala-aho R, Riihilä P, Kallajoki M, Grénman R, Peltonen J, Pihlajaniemi T, Heljasvaara R, Kähäri VM. (2011) Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma. *Am J Pathol* 179:1110–1119.
131. Toriseva M, Ala-aho R, Peltonen S, Peltonen J, Grénman R, Kähäri VM. (2012) Keratinocyte growth factor induces gene expression signature associated with suppression of malignant phenotype of cutaneous squamous carcinoma cells. *PLoS One* 7(3):e33041.
132. Toriseva M, Laato M, Carpén O, Ruohonen ST, Savontaus E, Inada M, Krane SM, Kähäri VM. (2012) MMP-13 regulates growth of wound granulation tissue and modulates gene expression signatures involved in inflammation, proteolysis, and cell viability *PLoS One* 7(8):e42596.
133. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemelä M, Khanna A, Chan EK, Kähäri VM, Kellokumpu-Lehtinen PL, Sansom OJ, Evan GI, Junttila MR, Ryan KM, Marine JC, Joensuu H, Westermarck J. (2013) Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. *Cancer Discov* 3:182-197
134. Leivonen SK, Lazaridis K, Decock J, Chantry A, Edwards DR, and Kähäri VM (2013) TGF- β -elicited induction of Tissue Inhibitor of Metalloproteinases (TIMP)-3 expression in fibroblasts involves complex interplay between Smad3, p38 α , and ERK1/2. *PLoS One* 8(2): e57474
135. Siljamäki E, Raiko L, Toriseva M, Nissinen L, Näreoja T, Peltonen J, Kähäri VM, Peltonen S (2014) p38 δ mitogen-activated protein kinase regulates the expression of tight junction protein ZO-1 in differentiating human epidermal keratinocytes. *Arch Dermatol Res* 306:131-41
136. Riihilä PM, Nissinen LM, Ala-aho R, Kallajoki M, Grénman R, Meri S, Peltonen S, Peltonen J, Kähäri VM (2014). Complement Factor H: a biomarker for progression of cutaneous squamous cell carcinoma. *J Invest Dermatol* 134:498-506.
137. Alpay K, Farshchian M, Tuomela J, Sandholm J, Aittokallio K, Siljamäki E, Kallio M, Kähäri VM, Hietanen S (2014). Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone. *PLoS One* 9(8):e105526
138. Riihilä P, Nissinen L, Farshchian M, Kivisaari A, Ala-aho R, Kallajoki M, Grénman R, Meri S, Peltonen S, Peltonen J, Kähäri VM. (2015) Complement factor I promotes progression of cutaneous squamous cell carcinoma. *J Invest Dermatol* 135:579-88.
139. Farshchian M, Nissinen L, Siljamäki E, Riihilä P, Toriseva M, Kivisaari A, Ala-aho R, Kallajoki M, Veräjänkorva E, Honkanen HK, Heljasvaara R, Pihlajaniemi T, Grénman R, Peltonen J, Peltonen S, Kähäri VM (2015). EphB2 promotes progression of cutaneous squamous cell carcinoma. *J Invest Dermatol* 135:1882-92.

140. Martins VL, Caley MP, Moore K, Szentpetery Z, Marsh ST, Murrell DF, Kim MH, Avari M, McGrath JA, Cerio R, Kivisaari A, Kähäri VM, Hodivala-Dilke K, Brennan CH, Chen M, Marshall JF, O'Toole EA. (2016) Suppression of TGF β and angiogenesis by type VII collagen in cutaneous SCC. *J Natl Cancer Inst* 108(1):djv293
141. Karppinen SM, Honkanen HK, Heljasvaara R, Riihilä P, Autio-Harmainen H, Sormunen R, Harjunen V, Väisänen MR, Väisänen T, Hurskainen T, Tasanen K, Kähäri VM, Pihlajaniemi T. (2016) Collagens XV and XVIII show different expression and localisation in cutaneous squamous cell carcinoma: type XV appears in tumor stroma while XVIII becomes upregulated in tumor cells and lost from microvessels. *Exp Dermatol* 25:348–354
142. Rousi E, Koskivuo I, Kaarela O, Kääriäinen M, Kähäri VM. (2016) Clinical and pathological aspects of melanoma among children in Finland. *Acta Dermatol Venereol* 96:718–720
143. Piipponen M, Nissinen L, Farshchian M, Riihilä P, Kivisaari A, Kallajoki M, Peltonen J, Peltonen S, Kähäri VM. (2016) Long Non-coding RNA PICSAR promotes growth of cutaneous squamous cell carcinoma by regulating ERK1/2 activity. *J Invest Dermatol* 136:1701-1710.
144. Lohcharoenka W, Harada M, Lovén J, Meisgen F, Landén NX, Zhang L, Nissinen L, Kähäri VM, Stähle M, Sonkoly E, Grander D, Arsenian-Henriksson M, Pivarcsi A. (2016) MicroRNA-203 inversely correlates with differentiation grade, targets c-MYC and functions as a tumor suppressor in cSCC. *J Invest Dermatol* 136, 2485-2494
145. Farshchian M, Nissinen L, Grénman R, Kähäri VM (2017) Dasatinib promotes apoptosis of cutaneous squamous carcinoma cells by regulating activation of ERK1/2. *Exp Dermatol* 26:89-92
146. Moilanen JM, Löffek S, Kokkonen N, Salo S, Väyrynen JP, Hurskainen T, Manninen A, Riihilä P, Heljasvaara R, Franzke CW, Kähäri VM, Salo T, Mäkinen MJ, Tasanen K. (2017) Significant role of collagen XVII and integrin β 4 in migration and invasion of the less aggressive squamous cell carcinoma cells. *Sci Rep* 7:45057
147. Riihilä P, Nissinen L, Farshchian M, Kallajoki M, Kivisaari A, Meri S, Grénman R, Peltonen S, Peltonen J, Pihlajaniemi T, Heljasvaara R, Kähäri VM. (2017) Complement components C3 and complement factor B promote growth of cutaneous squamous cell carcinoma. *Am J Pathol* 187:1186-1197.
148. Farshchian M, Nissinen L, Siljamäki E, Riihilä P, Piipponen M, Kivisaari A, Kallajoki M, Grénman R, Peltonen J, Peltonen S, Quint KD, Bouwes Bavinck JN, Kähäri VM. (2017) Tumor cell specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma. *Oncotarget* 8:45825-45836
149. Nissinen L, Siljamäki E, Riihilä P, Piipponen M, Farshchian M, Kivisaari A, Kallajoki M, Raiko L, Peltonen J, Peltonen S, Kähäri VM. (2017) Expression of claudin-11 by tumor cells in cutaneous squamous cell carcinoma is dependent on the activity of p38 δ . *Exp Dermatol* 26:771-777

150. Piipponen M, Heino J, Kähäri VM, Nissinen L (2018) Long Non-coding RNA PICSAR decreases adhesion and promotes migration of squamous carcinoma cells by downregulating $\alpha 2\beta 1$ and $\alpha 5\beta 1$ integrin expression. *Biol Open* 7(11) pii: bio037044.
151. Riihilä P, Viiklepp K, Nissinen L, Farshchian M, Kallajoki M, Kivisaari A, Meri S, Peltonen J, Peltonen S, Kähäri VM. (2018) Tumor cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma. (Submitted).
152. Caley M, Martins V, Moore K, Lashari M, Nissinen L, Kähäri VM, Alexander S, Harwood C, Jones J, Marshall J, and O'Toole E. Loss of laminin $\alpha 3$ expression in cutaneous SCC induces amoeboid invasion and increases macrophage recruitment to the tumour microenvironment (Submitted)

b. Reviews and book chapters

1. Heino J, Kähäri VM (1987) Interleukiini-1 ja sidekudosvauriot kroonisissa tulehduksissa. *Duodecim* 103: 621-623. (In Finnish)
2. Vuorio E, Kähäri VM (1988) Serum and cell factors modulating the connective tissue in scleroderma. Regulation of mRNA. In: Control mechanisms in scleroderma. The Arthritis & Rheumatism Council for Research, Conference Proceedings No.4:41-46.
3. Rosenbloom J, Bashir M, Yeh H, Rosenbloom J, Ornstein-Goldstein N, Fazio M, Kähäri VM, Uitto J (1991) Regulation of elastin gene expression. *Ann NY Acad Sci* 624:116-136.
4. Rosenbloom J, Bashir M, Kähäri VM, Uitto J (1991) Elastin genes and regulation of their expression. *Crit Rev Eukar Gene Expr* 1:145-156.
5. Kähäri VM, Reitamo S, Granlund H, Uitto J (1991) Ihon fibroottiset taudit. *Duodecim* 107: 957-970. (In Finnish)
6. Uitto J, Christiano AM, Kähäri VM, Bashir MM, Rosenbloom J (1991) Molecular biology and pathology of human elastin. *Biochem Soc Transact* 19:824-829.
7. Mauviel A, Kähäri VM, Chen YQ, Kurkinen M, Evans CH, Uitto J (1992) Transcriptional activation of fibroblast stromelysin-1 and collagenase gene expression by a novel lymphokine, leukoregulin. *Transact Am Assoc Phys.* CV:100-109.
8. Uitto J, Mauviel A, Kähäri VM (1993) Cytokine modulation of collagen and elastin gene expression. *Pharmacol Skin* 5:128-138.
9. Kähäri VM (1993) Activation of dermal connective tissue in scleroderma. *Ann Med* 25:511-518.
10. Uitto J, Fazio MJ, Kähäri VM (1993) Elastic fibers. In: *Connective Tissue Diseases of the Skin*. Eds. Lapière CM, Krieg T. Marcel Dekker Inc. New York, NY. pp 31-39.
11. Kähäri VM, Saarialho-Kere U. (1997) Matrix metalloproteinases in skin. *Exp Dermatol* 6: 199-213.

12. Varga J, Kähäri VM. (1997) Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders. *Curr Opin Rheumatol* 9:562-570.
13. Kähäri, VM, Johansson N, Grénman R, Airola K, Saarialho-Kere U. (1998) Expression of collagenase-3 (MMP-13) by tumor cells in squamous cell carcinomas of the head and neck. *Adv Exp Med Biol* 451: 63-68.
14. Ahonen M, Baker AH, Kähäri VM (1998) High level expression of tissue inhibitors of metalloproteinases-1, - 2 and -3 in melanoma cells achieved by adenovirus mediated gene transfer. *Adv Exp Med Biol* 451: 69-72.
15. Kähäri VM, Saarialho-Kere U. (1999) Matrix metalloproteinases and their inhibitors in tumour growth and invasion. *Ann Med* 31:34-45.
16. Westermarck J, Kähäri VM. (1999) Regulation of matrix metalloproteinase expression in tumor invasion. *FASEB J* 13:781-792.
17. Johansson N, Kähäri VM. (2000) Matrix metalloproteinases in squamous cell carcinoma. *Histol Histopathol* 15:225-237
18. Heino J, Kähäri VM. (2000) Cell Invasion – Cooperation between gene families at several levels. Editorial. *Cell Mol Life Sci* 57: 3-4
19. Johansson N, Ahonen M, Kähäri VM. (2000) Matrix metalloproteinases in tumor invasion. *Cell Mol Life Sci* 57: 5-15.
20. Baker AH, Ahonen M, Kähäri VM. (2000) Potential applications of tissue inhibitor of metalloproteinase (TIMP) overexpression for cancer gene therapy. In *Cancer Gene Therapy - Past Achievements and Future Prospects*, ed. Nagy Habib *Adv Exp Med Biol* 465:469-83
21. Ravanti L, Kähäri VM. (2000) Matrix metalloproteinases in wound repair. *Int J Mol Med* 6:391-407.
22. Hukkanen V, Kähäri VM, Hyypiä T. (2001) Virukset lääketieteen apuvälineinä. *Duodecim* (In Finnish) 117:1059-1065
23. Reunanen N, Kähäri VM. (2002) Matrix metalloproteinases in cancer cell invasion. In *Cell Invasion*, Eds. J. Heino, VM. Kähäri, Landes Bioscience, Georgetown, TX. 1-19.
24. Mori Y, Kähäri VM, Varga J. (2002) Scleroderma-like cutaneous syndromes. *Curr Rheumatol Rep* 4:113-122.
25. Vihinen P, Kähäri VM. (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. *Int J Cancer* 99:157-166.
26. Vihinen P, Kähäri VM. (2002) Matrix metalloproteinases and their inhibitors in melanoma. *Recent Res Devel Cancer* 4:379-393.
27. Iivanainen E, Kähäri VM, Heino J, Elenius K. (2003) Endothelial cell-matrix interactions. *Microsc Res Techn* 60:13-22.

28. Vihinen PP, Pyrhönen SO, Kähäri VM. (2003) New prognostic factors and developing therapy of cutaneous melanoma. *Ann Med* 35:66-78
29. Kähäri VM, Lauerma AI (2003) Ihotautien syntymekanismit. Kirjassa *Ihotaudit*, toim. M. Hannuksela, T. Reunala, R. Suhonen, Duodecim. Helsinki, Finland. pp. 23-34.
30. Lauerma AI, Kähäri VM (2003) Kutina. Kirjassa *Ihotaudit*, toim. M. Hannuksela, J. Karvonen, T. Reunala, R. Suhonen, Duodecim, pp. 59-63
31. Vihinen P, Kähäri VM, Pyrhönen S. (2004) Ihomelanooman ennustetekijät ja kehittyvät hoitomahdollisuudet *Duodecim* 120:1445-1456.
32. Vihinen P, Kähäri VM. (2004) Melanoma biomarkers – molecular profiling and its clinical implications. *Encyclopedia of Medical Genomics & Proteomics (EMGP)*, Eds. Fuchs J, Podda M. Marcel Dekker, USA, Vol. 2:785-790
33. Vihinen P, Ala-aho R, Kähäri VM. (2005) Matrix metalloproteinases as therapeutic targets in cancer. *Curr Cancer Drug Targets* 5:203-220
34. Ala-aho R, Kähäri VM. (2005) Collagenases in cancer. *Biochimie* 87:273-86.
35. Leivonen SK, Kähäri VM. (2007) Transforming growth factor- β signaling in cancer invasion and metastasis. *Int J Cancer* 121:2119-24.
36. Ala-aho R, Baker AH, Kähäri VM (2008) Targeting degradome genes via engineered viral vectors. In the Book: *The Cancer Degradome—Proteases and Cancer Biology*. (Eds. Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF). Springer. pp 877-894
37. Vihinen P, Ala-aho R, Kähäri VM. (2008) Diagnostic and prognostic role of matrix metalloproteinases in cancer. *Expert Opinion on Medical Diagnostics* Vol. 2, (9):1025-1039.
38. Toriseva M, Kähäri VM, (2009) Proteinases in cutaneous wound healing. *Cell Mol Life Sci* 66:203-24
39. Liippo J, Toriseva M, Kähäri VM. (2009) Natural killer cells in wound healing. In the book: *Natural killer cells* (Eds. Lotze M, Thomson A) Elsevier. pp. 519-524
40. Kähäri VM, Ala-Aho R. (2009) Stromal collagenase in melanoma: a vascular connection. *J Invest Dermatol* 129:2545-7.
41. Kähäri VM, Lauerma A (2011) Ihotaudit. Kirjassa *Kliininen farmakologia ja lääkehoito* (toim. Keränen T) Kandidaattikustannus, Helsinki
42. Toriseva M, Kähäri VM. (2012) Proteinases in wound healing. In the Book: *Extracellular Matrix: Pathobiology and Signaling*. (Ed. Nikos Karamanos). De Gruyter pp. 343-376
43. Nissinen L, Kähäri VM. (2012) ADAMTS5 – a new player in the vascular field. *Am J Pathol* 181:743-5

44. Kivisaari A, Kähäri VM (2013). Molekylära mekanismer vid skivepitelcancer i huden. *Finska Läkarsällskapets handlingar* 173:42-48
45. Kivisaari A, Kähäri VM (2013) Squamous cell carcinoma of the skin: Emerging need for novel biomarkers. *World J Clin Oncol* 4:85-90.
46. Kivisaari A, Kähäri VM (2014) Miten tunnistan ja hoidan aurinkokeratoosin (Diagnosis and treatment of actinic keratosis). *Suomen Lääkärilehti* 69:1321-1324.
47. Nissinen L, Kähäri VM. (2014) Matrix metalloproteinases in inflammation. *Biochim Biophys Acta* 1840:2571-80.
48. Nissinen L, Kähäri VM (2015). Collagen turnover in wound repair- A macrophage connection. *J Invest Dermatol* 135:2350-2
49. Nissinen L, Farshchian M, Riihilä P, Kähäri VM (2016). New perspectives on the role of tumor microenvironment in progression of cutaneous squamous cell carcinoma. *Cell Tissue Res* 365:691-702.
50. Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, Krieg T (2017) European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. *J Eur Acad Dermatol Venereol* 31:1401-1424
51. Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, Krieg T (2017) European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. *J Eur Acad Dermatol Venereol* 31:1581-1594

D. Publications intended for professional communities

1. Harvima I, Ranki A, Reunala T, Kähäri VM, Oikarinen A. Vastine Duodecimin pääkirjoitukseen »Miten ihotautien hoidon järjestelmää tulisi kehittää?» Duodecim. 2006;122:479
2. Barker J, Kähäri VM, Parks WC, Ranki A. (2010) Ulpu Saarialho-Kere (1960-2009). *J Invest Dermatol* 130:640.

Professor Veli-Matti Kähäri, M.D., Ph.D.

3. Healy E, Piguet V, Kähäri VM. (2010) Forty years of the European society for Dermatological Research as European Dermatology goes from strength to strength (Editorial). *J Invest Dermatol* 130:1957-9
4. Farshchian M, Kähäri VM. (2013) Novel biomarkers for progression of cutaneous squamous cell carcinoma. *Solubiologi* 1:15-19

E. Publications intended for the general public

1. Kähäri VM. (2000) Diabeettisen haavan kohdennettu geeniterapia. (In Finnish) *Diabetes* 9:22-23.

G. Doctoral thesis

Kähäri VM (1987) Regulation of procollagen gene expression in localized scleroderma. Studies on an activated fibroblast phenotype. Doctoral Thesis. University of Turku, 1-60. ISBN 951-99870-0-2.

H. Patents

1. Koskinen MK, Säilynoja ES, Ahola MS, Jalonen H, Salonen JI, Kähäri VM. Biodegradable carrier and method for preparation thereof. United States Patent 7485318, Feb 3 2009
2. Koskinen MK, Säilynoja ES, Ahola MS, Jalonen H, Salonen JI, Kähäri VM. Biodegradable carrier and method for preparation thereof. United States Patent 7727543, Jun 1 2010